269 related articles for article (PubMed ID: 17045418)
1. Is inflammation a contributor for coronary stent restenosis?
Li JJ; Nie SP; Zhang CY; Gao Z; Zheng X; Guo YL
Med Hypotheses; 2007; 68(5):945-51. PubMed ID: 17045418
[TBL] [Abstract][Full Text] [Related]
2. Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effects.
Li JJ; Li J; Nan JL; Li Z; Zhen X; Mu CW; Dai J; Zhang CY
Med Hypotheses; 2007; 69(5):1004-9. PubMed ID: 17499449
[TBL] [Abstract][Full Text] [Related]
3. Coronary stenting and inflammation.
Gaspardone A; Versaci F
Am J Cardiol; 2005 Dec; 96(12A):65L-70L. PubMed ID: 16399095
[TBL] [Abstract][Full Text] [Related]
4. Prevention of restenosis after stenting: the emerging role of inflammation.
Versaci F; Gaspardone A
Coron Artery Dis; 2004 Sep; 15(6):307-11. PubMed ID: 15346087
[TBL] [Abstract][Full Text] [Related]
5. Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent restenosis -- comparison with stable and unstable angina.
Kozinski M; Krzewina-Kowalska A; Kubica J; Zbikowska-Gotz M; Dymek G; Piasecki R; Sukiennik A; Grzesk G; Bogdan M; Chojnicki M; Dziedziczko A; Sypniewska G
Inflamm Res; 2005 May; 54(5):187-93. PubMed ID: 15953990
[TBL] [Abstract][Full Text] [Related]
6. Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury.
Scott NA
Adv Drug Deliv Rev; 2006 Jun; 58(3):358-76. PubMed ID: 16733073
[TBL] [Abstract][Full Text] [Related]
7. Drug-eluting stents.
García-García HM; Vaina S; Tsuchida K; Serruys PW
Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
[TBL] [Abstract][Full Text] [Related]
8. Contemporary treatment of in-stent restenosis and the incidence of recurrent in-stent restenosis in the era of drug-eluting stents.
Ajani AE; Yan BP; Clark DJ; Eccleston D; Walton A; Lew R; Meehan A; Brennan A; Reid C; Duffy SJ;
Heart Lung Circ; 2007 Aug; 16(4):269-73. PubMed ID: 17419097
[TBL] [Abstract][Full Text] [Related]
9. Drug-eluting stents: preventing restenosis.
Slavin L; Chhabra A; Tobis JM
Cardiol Rev; 2007; 15(1):1-12. PubMed ID: 17172878
[TBL] [Abstract][Full Text] [Related]
10. Recurrent in-stent restenosis is not associated with the angiotensin-converting enzyme D/I, angiotensinogen Thr174Met and Met235Thr, and the angiotensin-II receptor 1 A1166C polymorphism.
Gross CM; Perrot A; Geier C; Posch MG; Hassfeld S; Kramer J; Schmidt S; Derer W; Dietz R; Ozcelik C
J Invasive Cardiol; 2007 Jun; 19(6):261-4. PubMed ID: 17541127
[TBL] [Abstract][Full Text] [Related]
11. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Alfonso F; Pérez-Vizcayno MJ; Hernández R; Bethencourt A; Martí V; López-Mínguez JR; Angel J; Iñiguez A; Morís C; Cequier A; Sabaté M; Escaned J; Jiménez-Quevedo P; Bañuelos C; Suárez A; Macaya C;
J Am Coll Cardiol; 2008 Nov; 52(20):1621-7. PubMed ID: 18992651
[TBL] [Abstract][Full Text] [Related]
12. [Clinical value of inflammatory biomarkers after stent implantation].
Niccoli G; Montone RA; Ferrante G; Minelli S; Crea F
G Ital Cardiol (Rome); 2011 Oct; 12(10):635-44. PubMed ID: 21947106
[TBL] [Abstract][Full Text] [Related]
13. The evolving role of inflammatory biomarkers in risk assessment after stent implantation.
Niccoli G; Montone RA; Ferrante G; Crea F
J Am Coll Cardiol; 2010 Nov; 56(22):1783-93. PubMed ID: 21087705
[TBL] [Abstract][Full Text] [Related]
14. [Expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in the pig coronary artery injury model: comparison of plain old balloon angioplasty and stent implantation].
Shimizu N; Suzuki H; Wakabayashi K; Iso Y; Shibata M; Yorozuya M; Katagiri T; Takeyama Y
J Cardiol; 2004 Mar; 43(3):131-9. PubMed ID: 15067801
[TBL] [Abstract][Full Text] [Related]
15. Low basal levels of circulating adiponectin in patients undergoing coronary stenting predict in-stent restenosis, independently of basal levels of inflammatory markers: lipoprotein associated phospholipase A2, and myeloperoxidase.
Moldoveanu E; Mut-Vitcu B; Tanaseanu GR; Marta DS; Manea G; Kosaka T; Vidulescu C; Tanaseanu C
Clin Biochem; 2008 Dec; 41(18):1429-33. PubMed ID: 18930040
[TBL] [Abstract][Full Text] [Related]
16. Treatment of patients with in-stent restenosis.
Alfonso F; Pérez-Vizcayno MJ; Cruz A; García J; Jimenez-Quevedo P; Escaned J; Hernandez R
EuroIntervention; 2009 May; 5 Suppl D():D70-8. PubMed ID: 19736076
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone-eluting stent: an anti-inflammatory approach to inhibit coronary restenosis.
Liu X; De Scheerder I; Desmet W
Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):653-60. PubMed ID: 15350167
[TBL] [Abstract][Full Text] [Related]
18. Restenosis is not associated with stent length in a pig model of coronary stent implantation.
Koutouzis M; Papalois A; Kyrzopoulos S; Dafnomili P; Kyriakides ZS
Cardiol J; 2008; 15(5):458-62. PubMed ID: 18810722
[TBL] [Abstract][Full Text] [Related]
19. Successful recanalization of in-stent coronary chronic total occlusion by subintimal tracking.
Lee NH; Cho YH; Seo HS
J Invasive Cardiol; 2008 Apr; 20(4):E129-32. PubMed ID: 18398245
[TBL] [Abstract][Full Text] [Related]
20. Polymer stent coating for prevention of neointimal hyperplasia.
Billinger M; Buddeberg F; Hubbell JA; Elbert DL; Schaffner T; Mettler D; Windecker S; Meier B; Hess OM
J Invasive Cardiol; 2006 Sep; 18(9):423-6; discussion 427. PubMed ID: 16954581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
